clinical-microbiology-biotechnology-2019-keynote

2 / 3

allied
academies
June 12-13, 2019 | Edinburgh, Scotland
8th European Clinical Microbiology and Immunology Congress
&
3rd World congress on Biotechnology
Page 11
Microbiology: Current Research | Volume: 3 | ISSN: 2591-8036
Joint Event
Notes:
Sergey Suchkov1, 2, 5
Irina Zavestovskaya2, Shawn Murphy3, Hiroyuki Abe4, 5 ,
John Mendelsohn5 and William Thilly6
1Sechenov University, Russia
2Moscow Engineering Physical Institute (MEPhI), Russia
3Autoimmunity Research Foundation, USA
4ISPM, Tokyo, Japan
5Harvard Medical School, USA
6Massachusetts Institute of Technology, USA
Personalized and precision medicine as a unique healthcare model
through the view of biodesign and translational armamentarium of
the newest generation
Anew systems approach to diseased states and wellness
result in a new branch in the healthcare services,
namely, personalized and precision medicine (PPM). To
achieve the implementation of PM concept, it is necessary
to create a fundamentally new strategy based upon
the subclinical recognition of biopredictors of hidden
abnormalities long before the disease clinically manifests
itself.
Each decision-maker values the impact of their decision to
use PPM on their own budget and well-being, which may
not necessarily be optimal for society as a whole. It would
be extremely useful to integrate data harvesting from
different databanks for applications such as prediction
and personalization of further treatment to thus provide
more tailored measures for the patients resulting in
improved patient outcomes, reduced adverse events and
more cost-effective use of health care resources. A lack
of medical guidelines has been identified by the majority
of re-sponders as the predominant barrier for adoption,
indicating a need for the development of best practices
and guidelines to support the implementation of PPM.
Implementation of PPM requires a lot before the current
model “physician-patient” could be gradually displaced by
a new model “medical advisor-healthy person-at-risk”. This
is the reason for developing global scientific, clinical, social
and educational projects in the area of PPM to elicit the
content of the new branch.
Speaker Biography
Sergey Suchkov graduated from Astrakhan State Medical University and
awarded with MD, then in 1985 maintained his PhD at the I M Sechenov
MoscowMedical Academy and in 2001, maintained his doctorship degree
at the Nat Inst of Immunology, Russia. From 1987 through 1989, he was
a senior researcher at Koltzov Inst of Developmental Biology. From 1989
through 1995, he was a head of the lab of clinical immunology, Helmholtz
Eye Research Institute in Moscow. From 1995 through 2004, as a chair
of the dept for clinical immunology, Moscow Clinical Research Institute
(MONIKI). He has been trained at NIH; Wills Eye Hospital, PA, USA; Univ
of Florida in Gainesville; UCSF, S-F, CA, USA; Johns Hopkins University,
Baltimore, MD, USA. He was an executive secretary-in-chief of the editorial
board, biomedical science, an international journal published jointly by
the USSR Academy of Sciences and the Royal Society of Chemistry, UK.
At present, he is a chair, dept for personalized and translational medicine,
I M Sechenov First Moscow State Medical University. He is a member of
the: New York Academy of Sciences, USA; American Chemical Society
(ACS), USA; American Heart Association (AHA), USA; EPMA (European
Association for Predictive, Preventive and Personalized Medicine),
Brussels, EU; ARVO (American Association for Research in Vision and
Ophthalmology); ISER (International Society for Eye Research) and PMC
(Personalized Medicine Coalition), Washington, USA.
e:
Sergey Suchkov et al., Microbiol Curr Res, Volume 3
ISSN: 2591-8036